Business Context and Reporting Period
Company: CorMedix Inc. (CRMD)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: CorMedix is a biopharmaceutical company focused on commercializing DefenCath, an antimicrobial catheter lock solution approved by the FDA in November 2023. The product was launched commercially in the U.S. inpatient setting in April 2024 and the outpatient setting in July 2024. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Sept 30, 2024 Balance Sheet |
|---|---|---|---|
| Net Sales | $11,456 | $12,262 | - |
| Gross Profit | $10,770 | $10,247 | - |
| Gross Margin | 94% | 84% | - |
| Net Loss | $(2,777) | $(31,394) | - |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.54) | - |
| Cash & Cash Equivalents | - | - | $35,286 |
| Short-term Investments | - | - | $10,744 |
| Total Current Assets | - | - | $73,154 |
| Total Current Liabilities | - | - | $18,481 |
| Accumulated Deficit | - | - | $(353,094) |
Liquidity: As of September 30, 2024, the company held approximately $46.0 million in cash, cash equivalents, and short-term investments. Management estimates these funds are sufficient to operate for at least twelve months from the filing date.
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $11.5 million in revenue for the three months ended September 30, 2024, compared to $0 in the same period in 2023. This marks the first commercial revenue following the FDA approval and launch of DefenCath.
- Operating Expenses: Total operating expenses increased 34% to $14.1 million for the quarter (from $10.5 million in 2023) and 37% to $45.5 million for the nine-month period (from $33.3 million in 2023).
- Selling & Marketing: Increased 66% ($6.7M vs $4.1M) and 106% ($20.5M vs $10.0M) due to the commercial launch and sales force build-out.
- General & Administrative: Increased 76% ($6.6M vs $3.7M) and 83% ($22.9M vs $12.5M) driven by personnel and legal/compliance costs associated with commercialization.
- R&D: Decreased 73% ($0.7M vs $2.7M) and 80% ($2.2M vs $10.9M) as costs shifted to Cost of Sales or G&A following FDA approval.
- Balance Sheet: Trade receivables increased to $17.4 million (from $0) and inventory increased to $6.6 million (from $2.1 million) to support commercial sales. Accrued expenses rose significantly to $17.0 million (from $7.0 million), largely due to accrued gross-to-net deductions and a $2.0 million license agreement liability.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects to fund operations for at least 12 months using existing cash and expected commercial revenue. The company has $36.0 million remaining capacity under its At-The-Market (ATM) program and $100 million under its 2024 Shelf Registration Statement.
- Customer Concentration: A single customer accounted for 98% of revenue in Q3 2024 and 92% in the nine-month period. This customer also represents 100% of accounts receivable.
- Legal Proceedings: The company is defending against a consolidated securities class action lawsuit (filed 2021, amended 2024) alleging violations related to NDA submissions and FDA communications. A related shareholder derivative litigation is currently stayed pending the resolution of the class action.
- License Agreement: A $2.0 million liability was recorded for a milestone payment under the ND License Agreement, which was triggered by net sales milestones met in Q3 2024. Payment is expected within 12 months of attainment.
- Supply Chain: The company currently relies on a single FDA-approved supplier for each of its two key active pharmaceutical ingredients (taurolidine and heparin sodium) and is working to qualify alternate suppliers.
Investor Verification Checklist
- Revenue Sustainability: Verify the durability of the single customer relationship representing 98% of Q3 revenue and the timeline for diversifying the customer base.
- Cash Burn Rate: Monitor the net cash used in operating activities ($45.0M for nine months) against the $46.0M cash balance to assess runway without additional financing.
- Reimbursement Status: Confirm the status of CMS reimbursement codes (NTAP, TDAPA, OPPS pass-through) and their impact on net pricing and adoption rates.
- Legal Exposure: Track the progress of the securities class action litigation and potential settlement costs or impacts on management focus.
- Inventory Valuation: Review the $6.6 million inventory balance, noting that a significant portion ($6.2M) consists of pre-commercial inventory previously expensed as R&D, which impacts current gross margins.